COG ANBL0032
The trial that made anti-GD2 immunotherapy standard for children with high-risk neuroblastoma, improving survival by about 20 points.
2-year EFS 66% vs 46%; 2-year OS 86% vs 75% (NEJM 2010); long-term 5-year OS 73% vs 57% (Yu 2021). Randomisation stopped early for efficacy; approval 2015.
- 66 vs 46 out of 100 free of a major event at 2 years with Immunotherapy + isotretinoin compared with Isotretinoin; 20 more per 100.
- Roughly one extra person helped for every 5 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- The p-value (0.01) says a difference this large would rarely happen by chance; it does not say how large or how useful the difference is.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 86 vs 75 out of 100 alive at 2 years with Immunotherapy + isotretinoin compared with Isotretinoin; 11 more per 100.
- Roughly one extra person helped for every 9 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- The p-value (0.02) says a difference this large would rarely happen by chance; it does not say how large or how useful the difference is.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: High-risk neuroblastoma after transplant: ch14.18 (dinutuximab) + GM-CSF + IL-2 + isotretinoin vs isotretinoin alone. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
226 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survival at 2 yearsprimary | Immunotherapy + isotretinoin | 113 | 66% | — | 0.01 | link |
| Isotretinoin | 113 | 46% | ||||
| Overall survival at 2 years | Immunotherapy + isotretinoin | — | 86% | — | 0.02 | — |
| Isotretinoin | — | 75% |
Pages like this
not linked directly; found by shared links- InstitutionUC San Diego Moores Cancer Center
Shares Alice L. Yu, Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Children's Oncology Group (COG).
- InstitutionUniversity of Wisconsin Carbone Cancer Center
Shares Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PairingAnti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)
Shares Dinutuximab (ch14.18) / dinutuximab beta, GD2 (disialoganglioside), Neuroblastoma (paediatric).
- TrialCOG ANBL0532
Shares Julie R. Park, Children's Oncology Group (COG), Neuroblastoma (paediatric).
- CompanyY-mAbs Therapeutics
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaMake paediatric combination studies part of every relevant adult cancer drug approval
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- InstitutionSt. Jude Children's Research Hospital
Shares Julie R. Park, Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaAn international consortium pooling the outcome of every treated child with cancer
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.